Phantom Neuro is a neurotechnology company developing minimally invasive muscle-based interfaces that enable intuitive control of prosthetic limbs and robotic systems without brain surgery. This weekly summary reviews the company’s latest media exposure and clinical progress, highlighting how these developments may shape its path toward commercialization.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
During the week, Phantom Neuro gained visibility through a feature on the science and technology show Core Memory, hosted by Ashlee Vance. Founder and CEO Connor Glass appeared alongside upper limb amputee Alex Smith to demonstrate how the firm’s muscle-machine interface converts a user’s intent into real-time control of prosthetics and robotic devices.
The Core Memory segment emphasized that many patients with physical disabilities may not require brain implants to regain function via human-machine interfaces. By focusing on a minimally invasive implant that leverages muscle signals, Phantom Neuro is positioning its platform as a lower-risk alternative to more invasive neural interface approaches.
The episode also highlighted broader use cases, including assistive technologies, defense applications, and next-generation human-machine interaction. While specific customer contracts were not disclosed, the attention on defense and rehabilitation markets points to diversified demand potential across healthcare, government, and robotics ecosystems.
Separately, Phantom Neuro underscored strategic progress through a LifeSci Startup CEO Q&A featuring Connor Glass. In that interview, the company detailed its flagship platform, Phantom X, described as a scalable muscle-machine interface designed for intuitive control of prosthetics and robotic devices.
A key update from the LifeSci feature was news of a first-in-human clinical study approval in Australia. This regulatory milestone moves Phantom Neuro’s technology from concept toward early clinical validation, an essential step for building evidence required by regulators, payers, and prospective commercial partners.
The Australian study is expected to help the company generate data on safety and performance, which could support future reimbursement discussions and collaboration with prosthetics manufacturers and robotics firms. Demonstrated clinical outcomes will likely be critical for differentiating Phantom X in a crowded neurotechnology market.
For the week, Phantom Neuro’s developments centered on heightened media visibility and the advancement of its clinical roadmap. Together, the Core Memory exposure and Australian trial approval signal measured but meaningful progress toward establishing the company’s minimally invasive neurotech platform in both medical and industrial applications.